<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               6 ADVERSE REACTIONS<BR>               <BR>                  The adverse reaction profiles for pantoprazole sodium delayed-release oral suspension and pantoprazole sodium delayed-release tablets are similar.<BR>               <BR>               <BR>               <BR>                  <BR>                     <BR>                        The most frequently occurring adverse reactions are as follows:<BR>                        <BR>                           For adult use (>2%) are headache, diarrhea, nausea, abdominal pain, vomiting, flatulence, dizziness, and arthralgia. (6) <BR>                        <BR>                        <BR>                           To report SUSPECTED ADVERSE REACTIONS, contact Dr. Reddy’s Laboratories, Inc. at 1-888-375-3784 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.<BR>                        <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     <BR>                        6.1 Clinical Trial Experience<BR>                     <BR>                     <BR>                        Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. <BR>                        <BR>                           Adults<BR>                        <BR>                        Safety in nine randomized comparative US clinical trials in patients with GERD included 1,473 patients on oral pantoprazole sodium (20 mg or 40 mg), 299 patients on an H2-receptor antagonist, 46 patients on another proton pump inhibitor, and 82 patients on placebo. The most frequently occurring adverse reactions are listed in Table 3. <BR>                        <BR>                           Table 3: Adverse Reactions Reported in Clinical Trials of Adult Patients with GERD at a Frequency of > 2%<BR>                        <BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><BR>                           <col/><BR>                           <col/><BR>                           <col/><BR>                           <col/><BR>                           <tbody><BR>                              <tr><BR>                                 <td valign="top">&#160;<content styleCode="bold">&#160;</content><BR>                                 </td><BR>                                 <td valign="top">&#160;Pantoprazole Sodium<br/>(n=1473)<br/>%</td><BR>                                 <td valign="top">&#160;Comparators<br/>(n=345)<br/>%</td><BR>                                 <td valign="top">&#160;Placebo<br/>(n=82)<br/>%</td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="top">&#160;Headache</td><BR>                                 <td valign="top">&#160;12.2</td><BR>                                 <td valign="top">&#160;12.8</td><BR>                                 <td valign="top">&#160;8.5</td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="top">&#160;Diarrhea</td><BR>                                 <td valign="top">&#160;8.8</td><BR>                                 <td valign="top">&#160;9.6</td><BR>                                 <td valign="top">&#160;4.9</td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="top">&#160;Nausea</td><BR>                                 <td valign="top">&#160;7</td><BR>                                 <td valign="top">&#160;5.2</td><BR>                                 <td valign="top">&#160;9.8</td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="top">&#160;Abdominal pain</td><BR>                                 <td valign="top">&#160;6.2</td><BR>                                 <td valign="top">&#160;4.1</td><BR>                                 <td valign="top">&#160;6.1</td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="top">&#160;Vomiting</td><BR>                                 <td valign="top">&#160;4.3</td><BR>                                 <td valign="top">&#160;3.5</td><BR>                                 <td valign="top">&#160;2.4</td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="top">&#160;Flatulence</td><BR>                                 <td valign="top">&#160;3.9</td><BR>                                 <td valign="top">&#160;2.9</td><BR>                                 <td valign="top">&#160;3.7</td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="top">&#160;Dizziness</td><BR>                                 <td valign="top">&#160;3</td><BR>                                 <td valign="top">&#160;2.9</td><BR>                                 <td valign="top">&#160;1.2</td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="top">&#160;Arthralgia</td><BR>                                 <td valign="top">&#160;2.8</td><BR>                                 <td valign="top">&#160;1.4</td><BR>                                 <td valign="top">&#160;1.2</td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR>Additional adverse reactions that were reported for pantoprazole sodium in clinical trials with a frequency of ≤ 2% are listed below by body system: <BR>                        Body as a Whole: allergic reaction, pyrexia, photosensitivity reaction, facial edema<BR>                        Gastrointestinal: constipation, dry mouth, hepatitis<BR>                        Hematologic: leukopenia, thrombocytopenia<BR>                        Metabolic/Nutritional: elevated CK (creatine kinase), generalized edema, elevated triglycerides, liver enzymes elevated<BR>                        Musculoskeletal: myalgia<BR>                        Nervous: depression, vertigo<BR>                        Skin and Appendages: urticaria, rash, pruritus<BR>                        Special Senses: blurred vision <BR>                        <BR>                        <BR>                           Adverse reaction information in pediatric patients with erosive esophagitis associated with GERD is approved for Wyeth Pharmaceuticals Inc.’s pantoprazole sodium delayed-release tablets.  However, due to Wyeth Pharmaceuticals Inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.<BR>                        <BR>                        <BR>                            <BR>                           Zollinger-Ellison Syndrome<BR>                        <BR>                        In clinical studies of Zollinger-Ellison Syndrome, adverse reactions reported in 35 patients taking pantoprazole sodium 80 mg/day to 240 mg/day for up to 2 years were similar to those reported in adult patients with GERD.<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     <BR>                        6.2 Postmarketing Experience<BR>                     <BR>                     <BR>                        The following adverse reactions have been identified during postapproval use of pantoprazole sodium. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. <BR>                        These adverse reactions are listed below by body system:<BR>                        General Disorders and Administration Conditions: asthenia, fatigue, malaise  <BR>                        Hepatobiliary Disorders: hepatocellular damage leading to jaundice and hepatic failure <BR>                        Immune System Disorders: anaphylaxis (including anaphylactic shock) <BR>                        Investigations: weight changes <BR>                        Metabolism and Nutritional Disorders: hyponatremia, hypomagnesemia <BR>                        Musculoskeletal Disorders: rhabdomyolysis, bone fracture <BR>                        Psychiatric Disorders: hallucination, confusion, insomnia, somnolence <BR>                        Renal and Urinary Disorders: interstitial nephritis <BR>                        Skin and Subcutaneous Tissue Disorders: severe dermatologic reactions (some fatal), including erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis (TEN, some fatal), and angioedema (Quincke's edema)<BR>                     <BR>                     <BR>                  <BR>               <BR>            <BR>         </P></DIV></HTML>